Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085980 · ClinicalTrials.gov registry record · NA
Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy
A NA study of Vulvovaginal Atrophy, sponsored by El. En. SpA.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT02085980: Completed NA study of Vulvovaginal Atrophy, sponsored by El. En. SpA.
NCT02085980 is a NA study of Vulvovaginal Atrophy that has completed, run by El. En. SpA. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02085980, a NA study of Vulvovaginal Atrophy, has completed, sponsored by El. En. SpA.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and the efficacy of a laser in the treatment of vulvovaginal atrophy (VVA), that is to assess the change in the severity of the vaginal dryness symptom, by means of a visual analogic scale (10 cm VAS).
Primary Outcome
The main outcome of the study is the efficacy of the laser procedure, intended as the amelioration of 50% of the severity of the vaginal dryness at 12 months, compared with baseline. The change in the vaginal dryness symptom has been assessed by means of a visual analogic scale (10 cm VAS).
Conditions Studied
Interventions
- DEVICE Laser treatment
Study Locations (2)
California
- Stanford University - Palo Alto
Ohio
- The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital - West Chester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02085980 record still lists
NCT02085980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Vulvovaginal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Laser treatment is the first listed.
NCT02085980 reports a single indexed study location in California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02085980 about?
NCT02085980 is a clinical study titled "Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy". The purpose of this study is to assess the safety and the efficacy of a laser in the treatment of vulvovaginal atrophy (VVA), that is to assess the change in the severity of the vaginal dryness symptom, by means of a visual analogic scale (10 cm VAS).
What is the current status of trial NCT02085980?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-03. Estimated completion is 2015-11.
What conditions does trial NCT02085980 study?
This clinical trial studies the following conditions: Vulvovaginal Atrophy.
What interventions are being tested in trial NCT02085980?
The interventions under investigation include: Laser treatment (DEVICE).
Who is sponsoring clinical trial NCT02085980?
This trial is sponsored by El. En. SpA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02085980 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvovaginal Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02085980's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia